Company intelligence / Profile preview

M-OPT

South Yarra, Victoria, Australiacollinsdictionary.com ↗

Ownership: Private
Employees: ~33
Development stage: Other

Overview

Opthea’s lead candidate, sozinibercept (OPT‑302), is a first-in-class VEGF-C/D inhibitor in Phase 3 trials for wet AMD and DME. It is being developed to complement standard anti–VEGF-A therapies, aiming to deliver superior vision outcomes. No commercial products yet; pivotal trial results are pending.

Therapeutic areas: Ophthalmology
Modalities: BiologicProtein
Industry: Biotech

Beyond the preview

Go deeper on M-OPT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on M-OPT.

Explore the full profile